Printer-friendly version
DermaPure® is 99% DNA-free decellularized dermal allograft with vascular-like channels and an intact ECM necessary to signal a cellular response to healing.
• Produced using patented dCELL® Technology
• Human-derived dermal allograft
• Minimally manipulated to maintain structure
• 99% DNA-free
• Biocompatible while retaining native growth factors, collagen and elastin, preserving natural structure
• Replaces the damaged extracellular matrix so living cells can flourish
• Supports angiogenesis with the presence of vascular-like channels present prior to application
• Permits fibroblasts to attach to the scaffold
• Contains the correct extracellular matrix components to attract and proliferate endothelial cells
DermaPure® Decellularized Dermal Allograft provides a scaffold for the body’s repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
See package insert/Instructions for Use.
See package insert/Instructions for Use.
Ambient temperature.
Decellularized human dermis
| Assigned HCPCS code | ● |
| Cryopreserved | |
| Dehydrated | |
| Desiccated | |
| Flowable | |
| Micronized | |
| Sheet form | ● |
| Requires refrigeration | |
| Shelf life greater than 2 years | ● |
| Shelf life limited | |
| Indicated for acute wounds | ● |
| Indicated for chronic wounds | ● |
| Indicated for diabetic ulcers | ● |
| Indicated for pressure ulcers | ● |
| Indicated for surgical wounds | ● |
| Indicated for third-degree burns | ● |
| Indicated for venous ulcers | ● |
| Contact manufacturer for usage guidelines | ● |
| Educational Material Available | ● |
| Free Samples/Trials Available | ● |
| Published Clinical Article Available | ● |
Acute Wounds
Burns
Cavity Wounds
Chronic Wounds
Deep Wounds
Dehisced Wounds
Diabetic Foot
Granulating/Epithelializing Wounds
Infected Wounds
Moderate/Highly Exudating Wounds
Non/Minimally Exudating Wounds
Palliative Wounds
Pressure Ulcers
Superficial Wounds
Surgical Wounds
Venous Ulcers
Single application in most cases. Additional applications at physician discretion.
Primary dressing: Non-adherent contact layer. Bolster, first five to seven days post application: Normal saline-moistened gauze or hydrogel-moistened gauze. Secondary dressing: Maintain a moist wound environment (e.g., foam dressing).
TRX Biosurgery is an innovative company in the field of regenerative medicine. The potential technology applications can address clinical needs such as wound care, vascular disease, heart valve replacement and knee repair.